Literature DB >> 28290754

Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.

Marwan Sheikh-Taha1, Lourdes C Corman2.   

Abstract

Nocardia is a Gram-positive aerobic pathogen that usually affects immunocompromised patients. We report a case of pulmonary infection caused by a rare Nocardia species, Nocardia beijingensis, in a 50-year-old woman who had received alemtuzumab for the treatment of her multiple sclerosis. The invasive pulmonary infection was successfully treated with meropenem.

Entities:  

Keywords:  Alemtuzumab; Nocardia beijingensis; multiple sclerosis; nocardiosis

Mesh：

Substances：

Year:  2017        PMID： 28290754     DOI： 10.1177/1352458517694431

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  14 in total

Review 1.  [New aspects of immunotherapy in multiple sclerosis].

Authors:  K Pape; F Zipp; S Bittner
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

Review 2.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 3.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

4.  Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.

Authors:  Cristian Deana; Daniele Bagatto; Alessandra Battezzi; Davide Pecori; Simone Lorenzut; Francesco Tuniz
Journal:  J Neurol       Date:  2022-03-30       Impact factor: 6.682

Review 5.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

6.  Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.

Authors:  Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Luigina Musu; Eleonora Cocco
Journal:  J Neurol       Date:  2019-03-12       Impact factor: 4.849

Review 7.  Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Authors:  Eva Havrdova; Jeffrey A Cohen; Dana Horakova; Ivana Kovarova; Eva Meluzinova
Journal:  Ther Clin Risk Manag       Date:  2017-10-16       Impact factor: 2.423

Review 8.  Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.

Authors:  Simon Faissner; Ralf Gold
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 6.497

9.  Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.

Authors:  Tjalf Ziemssen; Katja Thomas
Journal:  Ther Adv Neurol Disord       Date:  2017-08-04       Impact factor: 6.570

Review 10.  Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Authors:  Cristina Guarnera; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2017-07-14       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.